期刊文献+

超选择性动脉化疗栓塞术治疗雄激素非依赖性前列腺癌 被引量:2

Superselective arterial chemoembolization for treatment of androgen-independent prostate cancer
下载PDF
导出
摘要 目的观察经前列腺动脉化疗栓塞术在治疗雄激素非依赖性前列腺癌(AIPC)中的临床应用。方法 23例AIPC患者随机分为介入组(12例)和对照组(11例),对照组给予雌莫司汀+紫三醇化疗,介入组在给予化疗的同时采用聚乙烯醇(PVA)颗粒栓塞前列腺动脉。结果介入组9例双侧前列腺动脉栓塞成功,3例仅栓塞单侧前列腺动脉;12例前列腺癌引起的血尿消失,双侧栓塞的9例在2个月后血PSA下降>50%,前列腺体积有不同程度缩小,疼痛缓解。对照组11例中7例疼痛减轻,2例肉眼血尿消失,6例PSA下降>50%,前列腺体积无变化。所有患者主要不良反应为恶心、呕吐、发热、会阴部及臀部和下腹部轻度疼痛,经对症处理后缓解或短期内自行缓解。结论超选择性前列腺动脉化疗栓塞对AIPC患者症状的改善和生活质量的提高具有重要意义。 Objective To observe the clinical application of superselective arterial chemoembolization for treatment of androgen-independent prostate cancer(AIPC).Methods Twenty-three patients with AIPC were randomly divided into 2 groups:Treatment group(12 patients)and control group(11 patients).In control group,prostatic arterial chemotherapy with paclitaxel and estramustine phosphate was performed,while superselective arterial chemoembolization combined with chemotherapy was performed for the treatment group.Results In the treatment group,both side prostatic arteries were successfully embolized in 9 patients,and single prostatic artery was embolized in 3 patients.Hematuria disappeared in all 12 patients.PSA descended more than 50% in 9 patients whose both side prostatic arteries were treated,while the prostate volume reduced and the pain was released.In control group,pain was released in 7 patients,macroscopic hematuria disappeared in 2 patients and PSA had got down more than 50% in 6 patients,but the prostate volume did not changed.The main side effects included nausea,vomiting,fever,slight pain in perineum,breech and lower abdomen.Conclusion Superselective arterial chemoembolization is effective for relieving the symptom and improving the quality of life in the patients with AIPC.
出处 《中国介入影像与治疗学》 CSCD 2010年第4期370-373,共4页 Chinese Journal of Interventional Imaging and Therapy
关键词 前列腺肿瘤 化学栓塞 治疗性 Prostatic neoplasms Chemoembolization therapeutic
  • 相关文献

参考文献14

  • 1李飞宇,王霄英,肖江喜,蒋学祥.中国男性前列腺癌MRS体素诊断标准[J].中国医学影像技术,2009,25(5):833-836. 被引量:27
  • 2蒋学祥,王霄英.国内前列腺癌的MRI和fMRI研究评价[J].中国医学影像技术,2004,20(8):1149-1149. 被引量:2
  • 3Jernal A,Murray T,Samuel A,et al.Cancer statistics 2003.Cancer Clin,2003,53(1):5-26.
  • 4Patel P,Ashdown D,James N,et al.Is gene therapy the answer for prostate cancer.Prostate Cancer Prostatic Dis,2004,7(Suppl):S14-19.
  • 5Franca CA,Vieira SL,Bernabe AJ,et al.The seven-year preliminary results of brachytherapy with Iodine-125 seeds for localized prostate cancer treated at a Brazilian single-cencer.Int Braz J Urol,2007,33(6):752-762.
  • 6Kupelian PA,Langen KM,Zeidan OA,et al.Daily variations in delivered doses in patients treated with radiotherapy for localized prostate cancer.Int J Radiat Oncol Biol Phys,2006,66(3):876-882.
  • 7Zelefsky MJ,Chan H,Hunt M,et al.Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.J Urol,2006,176(4 Pt1):1415-1419.
  • 8Vargas C,Fryer A,Mahajan C,et al.Dose-volume comparism of proton therapy and intensity-modulated radiotherapy for prostate cancer.Int J Radiat Oncol Biol Phys,2008,70(3):744-751.
  • 9高江平,洪宝发.雄激素非依赖性前列腺癌的治疗策略[J].中华泌尿外科杂志,2005,26(4):286-287. 被引量:7
  • 10柯雪梅,朱康顺.盆腔血管性栓塞治疗的严重并发症分析[J].介入放射学杂志,2004,13(4):320-321. 被引量:18

二级参考文献33

共引文献57

同被引文献21

  • 1Hang P , Bektic J , Bart seh G, et aL Androgen receptor down reg- ulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol. 2005 ;96(3 -4) :251 - 258.
  • 2Hirawat S , Budman DR , Kreis W. The androgen receptor :structure , mu2tations , and antiandrogens. Cancer Invest. 2003 ; 21(3) :400 -417.
  • 3So A, G leave hi, H urtado - Col A, et al. Mechanisms of the de- velopment of androgen independence in prostate cancer. World JU rol. 2005 ;23 : 1 - 9.
  • 4Kenji Hiraoka, Hiroaki Miyazaki, Naomi Niisato, et al. Chloride Ion Modulates Cell Proliferation of Human Androgen - independent Prostatic Cancer Cell. Cell Physiol Biochem. 2010 ;25:379 - 388.
  • 5l'etrylak D, Tangen C, Hussain M, et al. Docetaxel and estramus- tine compared with mitoxantrone and prednisone for advanced re- fractory prostate cancer. N Engl J Med. 2004 ;351:1513 -1520.
  • 6Tannock I, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502 - 1512.
  • 7Figg WD, Li H, Sissung T, et al. Pie -clinical and clinical eval- uation of estramustine, docetaxel and thalidomide combination in androgen - independent prostate cancer. BJU Int. 2007 ; 99 : 1047 - 1055.
  • 8Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus predni- sone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med .2004;351(15) :1502 -1512.
  • 9Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and es- tramustine compared with mitoxantrone and prednisone for ad- vanced refractory prostate cancer. N Engl J Med. 2004 ;351 ( 15 ) : 1513 - 1520.
  • 10Chiappino I, Destefanis P, Addeo A, et al. Activity of weekly paclitaxel in advanced hormone - refractory prostate cancer. Am J Clin Oncol. 2007 ;30:234 - 238.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部